At the International Biotechnology Achievement Forum 2025 in Riyadh, Dr. George Syrmalis, Chief Executive Officer of Bioscience Equity Partners, delivered a keynote address as a member of the Biotechnology Venture Readiness Program.
In his remarks to founders, scientists, policymakers, and institutional stakeholders, Dr. Syrmalis shared a structured investor perspective on what professional biotech and healthtech investors look for when assessing whether a company is fundable, investable, and capable of scaling responsibly
Watch the full video below:
Dr. Syrmalis emphasized that institutional capital does not invest in ideas, but in clearly defined execution paths supported by evidence, regulatory realism, and disciplined governance. He highlighted that innovation without a well-defined, economically meaningful problem is not investable, and that technological novelty alone does not constitute differentiation.
A central theme of the address was the importance of defensible advantages, credible data, and a deep understanding of regulatory pathways. In biotechnology and healthtech, evidence is the currency of credibility, while regulation is not an obstacle to be avoided, but a core component of the investment thesis.
Referencing Saudi Arabia’s long-term commitment to life sciences under Vision 2030, Dr. Syrmalis underscored that capital aligned with national strategy seeks companies capable of becoming long-term institutional contributors, not short-term experiments.
He concluded by noting that fundraising is not an event, but a consequence of preparation, discipline, and respect for capital. The companies that succeed are not the loudest, but the clearest, most credible, and most execution-ready.
